SSCRIPTURAclinical · decision · supportScriptura
Sign in
Patient sign inClinician sign in
Back to peptide rules

Tesamorelin

Regulatory status by US jurisdiction. Reviewed and signed by a clinician. Not a dosing guide, not legal advice, and not a device.

Scriptura flags, alerts, and informs. The prescribing clinician makes every decision.

Federal posture

  • FDA approved for a specific indication.
  • 503A bulks list: Never listed on the 503A bulks list.
  • DEA schedule: Not scheduled.

Status by jurisdiction

JurisdictionStatusVerified
AlabamaNo compound specific state restriction2026-07-10
AlaskaNo compound specific state restriction2026-07-10
ArizonaNo compound specific state restriction2026-07-10
ArkansasNo compound specific state restriction2026-07-10
CaliforniaNo compound specific state restriction2026-07-10
ColoradoNo compound specific state restriction2026-07-10
ConnecticutNo compound specific state restriction2026-07-10
DelawareNo compound specific state restriction2026-07-10
District of ColumbiaNo compound specific state restriction2026-07-10
FloridaNo compound specific state restriction2026-07-10
GeorgiaNo compound specific state restriction2026-07-10
HawaiiNo compound specific state restriction2026-07-10
IdahoNo compound specific state restriction2026-07-10
IllinoisNo compound specific state restriction2026-07-10
IndianaNo compound specific state restriction2026-07-10
IowaNo compound specific state restriction2026-07-10
KansasNo compound specific state restriction2026-07-10
KentuckyNo compound specific state restriction2026-07-10
LouisianaNo compound specific state restriction2026-07-10
MaineNo compound specific state restriction2026-07-10
MarylandNo compound specific state restriction2026-07-10
MassachusettsNo compound specific state restriction2026-07-10
MichiganNo compound specific state restriction2026-07-10
MinnesotaNo compound specific state restriction2026-07-10
MississippiNo compound specific state restriction2026-07-10
MissouriNo compound specific state restriction2026-07-10
MontanaNo compound specific state restriction2026-07-10
NebraskaNo compound specific state restriction2026-07-10
NevadaNo compound specific state restriction2026-07-10
New HampshireNo compound specific state restriction2026-07-10
New JerseyNo compound specific state restriction2026-07-10
New MexicoNo compound specific state restriction2026-07-10
New YorkNo compound specific state restriction2026-07-10
North CarolinaNo compound specific state restriction2026-07-10
North DakotaNo compound specific state restriction2026-07-10
OhioNo compound specific state restriction2026-07-10
OklahomaNo compound specific state restriction2026-07-10
OregonNo compound specific state restriction2026-07-10
PennsylvaniaNo compound specific state restriction2026-07-10
Puerto RicoNo compound specific state restriction2026-07-10
Rhode IslandNo compound specific state restriction2026-07-10
South CarolinaNo compound specific state restriction2026-07-10
South DakotaNo compound specific state restriction2026-07-10
TennesseeNo compound specific state restriction2026-07-10
TexasNo compound specific state restriction2026-07-10
UtahNo compound specific state restriction2026-07-10
VermontNo compound specific state restriction2026-07-10
VirginiaNo compound specific state restriction2026-07-10
WashingtonNo compound specific state restriction2026-07-10
West VirginiaNo compound specific state restriction2026-07-10
WisconsinNo compound specific state restriction2026-07-10
WyomingNo compound specific state restriction2026-07-10

The verified date is the date the reviewer confirmed the status against public sources. It is not a state board confirmation. The prescribing clinician owns the compliance decision.

Read the federal timeline for peptide compounding, July 2026.
Reviewed and signed
Clinical review: Sabrina Runbeck, MPH, MHS, PA-C, Clinical Director, Scriptura Health, on 2026-07-22.
Subject matter: Sabrina Runbeck, MPH, MHS, PA-C, Clinical Director, Scriptura Health, on 2026-07-22.
Verified against public sources on 2026-07-24.

Get Scriptura in your clinic

See how Scriptura pulls federal, state, and clinical sources into one reviewed view for prescribing clinicians. Book a live walkthrough, or get short updates when the rules move.

Reviewed by Sabrina Runbeck, MPH, MHS, PA-C, Clinical Director, Scriptura Health.

Tesamorelin regulatory status by US jurisdiction | Scriptura Health